Novozymes A/S (OTCMKTS:NVZMY) Upgraded by Barclays to “Strong-Buy” Rating

Barclays upgraded shares of Novozymes A/S (OTCMKTS:NVZMY) to a strong-buy rating in a research report report published on Monday,Zacks.com reports.

A number of other research firms have also recently commented on NVZMY. Citigroup cut Novozymes A/S from a “neutral” rating to a “sell” rating in a research note on Thursday, October 17th. Berenberg Bank raised Novozymes A/S to a “strong-buy” rating in a research note on Tuesday, September 24th.

Novozymes A/S Stock Performance

Shares of NVZMY stock opened at $56.53 on Monday. The firm has a market cap of $26.47 billion, a P/E ratio of 35.78, a P/E/G ratio of 3.87 and a beta of 0.90. The firm’s 50 day moving average price is $65.88 and its 200-day moving average price is $63.85. Novozymes A/S has a one year low of $49.99 and a one year high of $72.50.

Novozymes A/S Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Wednesday, September 18th. Investors of record on Monday, September 9th were issued a $0.1678 dividend. The ex-dividend date was Monday, September 9th. Novozymes A/S’s dividend payout ratio (DPR) is currently 41.77%.

Novozymes A/S Company Profile

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.